Europe Acute Myeloid Leukemia Treatment Market Size & Outlook
The acute myeloid leukemia treatment market in Europe is expected to reach a projected revenue of US$ 1,824.7 million by 2030. A compound annual growth rate of 10.3% is expected of Europe acute myeloid leukemia treatment market from 2024 to 2030.
Revenue, 2023 (US$M)
$932.4
Forecast, 2030 (US$M)
$1,824.7
CAGR, 2024 - 2030
10.3%
Report Coverage
Europe
Related Markets
Europe acute myeloid leukemia treatment market highlights
- The Europe acute myeloid leukemia treatment market generated a revenue of USD 932.4 million in 2023.
- The market is expected to grow at a CAGR of 10.1% from 2024 to 2030.
- In terms of segment, myeloblastic leukemia was the largest revenue generating disease in 2023.
- Myeloblastic Leukemia is the most lucrative disease segment registering the fastest growth during the forecast period.
Europe data book summary
| Market revenue in 2023 | USD 932.4 million |
| Market revenue in 2030 | USD 1,824.7 million |
| Growth rate | 10.1% (CAGR from 2024 to 2030) |
| Largest segment | Myeloblastic leukemia |
| Fastest growing segment | Myeloblastic Leukemia |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Myeloblastic Leukemia |
| Key market players worldwide | Astellas Pharma Inc, Bristol-Myers Squibb Co, Celgene, Daiichi Sankyo Co Ltd, Jazz Pharmaceuticals PLC, Novartis AG ADR, Otsuka Pharmaceutical, Pfizer Inc, Rigel Pharmaceuticals Inc, Merck & Co Inc, Sanofi SA |
Other key industry trends
- In terms of revenue, Europe region accounted for 29.3% of the global acute myeloid leukemia treatment market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,581.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Acute Myeloid Leukemia Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Jazz Pharmaceuticals PLC | View profile | 2800 | Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, Ireland, D04 E5W7 | https://www.jazzpharmaceuticals.com |
| Rigel Pharmaceuticals Inc | View profile | 147 | 611 Gateway Boulevard, Suite 900, South San Francisco, CA, United States, 94080 | https://www.rigel.com |
| Celgene | View profile | 10001+ | Summit, New Jersey, United States, North America | https://www.bms.com |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Daiichi Sankyo Co Ltd | View profile | 17435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | https://www.daiichisankyo.com |
| Otsuka Pharmaceutical | View profile | 251-500 | Tokyo, Tokyo, Japan, Asia | https://www.otsuka.co.jp/en/ |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
